No connection

Search Results

GOSS vs TCRX

GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%
TCRX
TScan Therapeutics, Inc.
BEARISH
Price
$1.43
Market Cap
$85.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GOSS
--
TCRX
--
Forward P/E
GOSS
-2.23
TCRX
-1.86
P/B Ratio
GOSS
-0.71
TCRX
0.66
P/S Ratio
GOSS
1.8
TCRX
8.32
EV/EBITDA
GOSS
-0.94
TCRX
-0.18

Profitability

Gross Margin
GOSS
100.0%
TCRX
0.0%
Operating Margin
GOSS
-333.65%
TCRX
-851.5%
Profit Margin
GOSS
0.0%
TCRX
0.0%
ROE
GOSS
--
TCRX
-71.28%
ROA
GOSS
-41.86%
TCRX
-27.88%

Growth

Revenue Growth
GOSS
47.1%
TCRX
286.0%
Earnings Growth
GOSS
--
TCRX
--

Financial Health

Debt/Equity
GOSS
--
TCRX
0.76
Current Ratio
GOSS
2.64
TCRX
8.41
Quick Ratio
GOSS
2.36
TCRX
8.15

Dividends

Dividend Yield
GOSS
--
TCRX
--
Payout Ratio
GOSS
0.0%
TCRX
0.0%

AI Verdict

GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%
TCRX BEARISH

TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).

Strengths
Exceptionally high liquidity (Current Ratio 8.41)
Significant YoY revenue growth of 286%
Recent trend of beating EPS estimates (3/4 last quarters)
Risks
Zero Piotroski F-Score indicating systemic financial weakness
Extreme operational inefficiency (Operating Margin -851.50%)
Negative ROE of -71.28% showing rapid equity erosion

Compare Another Pair

GOSS vs TCRX: Head-to-Head Comparison

This page compares Gossamer Bio, Inc. (GOSS) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile